Economic Assessment of Different Modalities of Immunoglobulin Replacement Therapy

Membe, Stephen K; Ho, Chuong; Cimon, Karen; Morrison, Andra; Kanani, Amin; Roifman, Chaim M.

doi:10.1016/j.iac.2008.06.008

Cited by 35 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With this current system it is no surprise that patients ranked costs as the second or third most important concern regarding home therapy (Table 4) and that the most concerned patients werethose 35 years of age and older and those receiving their therapy in the community (Figures 1 and 3). Many reports out of Europe and the United States have indicated a cost savings or at least a breakeven budget for a self-infusion system (Ochs et al 1987;Sorensen et al 1987;Ryan et al 1988;Gardulf et al 1995b;Kobayashi et al 1990;Gaspar et al 1998;Högy et al 2005;Membe et al 2008). A recent Canadian cost assessment comparing home-to hospital-based treatment revealed some marginal cost savings for home-based IVIG or SCIG replacement (Membe et al 2008).…”

Section: Costsmentioning

confidence: 99%

“…Many reports out of Europe and the United States have indicated a cost savings or at least a breakeven budget for a self-infusion system (Ochs et al 1987;Sorensen et al 1987;Ryan et al 1988;Gardulf et al 1995b;Kobayashi et al 1990;Gaspar et al 1998;Högy et al 2005;Membe et al 2008). A recent Canadian cost assessment comparing home-to hospital-based treatment revealed some marginal cost savings for home-based IVIG or SCIG replacement (Membe et al 2008). However, it remains uncertain whether costs for home-based treatment will be fully recovered from the government-owned insurer.…”

Section: Costsmentioning

confidence: 99%

See 1 more Smart Citation

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

ReidBrenda

PiresLinda

2014

LymphoSign Journal

View full text Add to dashboard Cite

Introduction: For close to half a century immunoglobulin replacement therapy has been the main therapy for patients unable to produce functioning antibodies. To date, both subcutaneous (SC) and intravenous delivery methods have been successful at effectively and safely replacing immunoglobulin. Home intravenous and SC therapy programs have been established and have gained attention, but the true motivation and frequency of switching from traditional hospital-based treatment to these alternatives remains unknown. This study aims to determine the willingness of patients in Canada to switch to a home-based gammaglobulin treatment program by quantifying related experiences and preferences.

show abstract

Section: Costsmentioning

confidence: 99%

Section: Costsmentioning

confidence: 99%

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

ReidBrenda

PiresLinda

2014

LymphoSign Journal

View full text Add to dashboard Cite

show abstract

“…Usually a 4 -6 session training course is required for home-based infusion preparation by the patients or their family. Medical and nursing follow-up care and support is offered during training (13). SCIg requires a nurse for patient training (6 hours during the first year) and for annual follow-up (6 hours).…”

Section: Resultsmentioning

confidence: 99%

Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

et al. 2017

View full text Add to dashboard Cite

Background: Immunoglobulin (Ig) replacement therapy is used for treating a variety of primary immunodeficiency diseases (PIDs). Ig replacement therapy is the most important therapy for these diseases, since it protects the body against infections and reduces autoimmune disease symptoms. The purpose of this research was to estimate the cost of subcutaneous and intravenous Ig therapy in Iran. Methods: This study is carried out from the perspective of Iran's healthcare system and all the medical costs are calculated. Cost variables include personnel, equipment, and supplies. The data required for cost estimation are obtained from the records of children's Medical center of Tehran for 2015. Personnel and medical treatment costs are calculated based on relative value units. For SCIg, cost items are extracted from the literature. Results: The total cost of IVIg and SCIg for the health system in the first year of treatment is $1370 and $121 respectively. The results indicate that SCIg reduces costs and is the preferred treatment for PID patients. Conclusions: SCIg therapy significantly reduces the costs of the healthcare system compared to IVIg therapy, and this is enough economic justification for introduction of this treatment in the Iranian healthcare system. SCIg is also critical in reducing the direct costs of patients.

show abstract

“…The intravenous route allows larger immunoglobulin doses to be administered, enables a fast onset of action, and has been demonstrated to be safe, effective, and well-tolerated [3]. However, adverse events may occur, administration in patients with poor venous access is difficult, and the cost of intravenous infusion is high [17].…”

Section: Discussionmentioning

confidence: 99%

Kiovig for primary immunodeficiency: Reduced infusion and decreased costs per infusion

Connolly¹,

Simoens²

2011

International Immunopharmacology

View full text Add to dashboard Cite

Economic Assessment of Different Modalities of Immunoglobulin Replacement Therapy

Cited by 35 publications

References 17 publications

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

Kiovig for primary immunodeficiency: Reduced infusion and decreased costs per infusion

Contact Info

Product

Resources

About